As the leading company in the Saudi private market and the second leading generic in MENA, Tabuk Pharmaceuticals is delivering on its commitment to promoting well-being and consistently enhancing healthcare outcomes. The company is a fully owned subsidiary of Astra Industrial Group, a publicly traded company on the Saudi stock exchange. Its manufacturing sites produce over 2 billion base units annually to help maintain the health of millions of patients across 17 countries in the MENA region.
Cyborg Score Rationale
Tabuk holds the #1 position in Saudi private pharma and #2 in MENA generics, with established manufacturing scale (2+ billion units/year), regional footprint (17 countries), and R&D capabilities. Revenue ($72M as of 2026) and workforce (2,400+ employees) reflect operational maturity. Strategic partnerships and recent awards signal innovation momentum, though private ownership and generic focus limit growth acceleration compared to integrated or specialty-focused peers.
Top Insights
Leading player in Saudi private pharmaceutical market and second-largest generic player in MENA
Manufacturing capacity exceeds 2 billion base units annually across four sites in Saudi Arabia, Sudan, and Algeria
R&D pipeline expanding into oncology, immunology, and ophthalmology beyond current therapeutic focus areas
Backed by Astra Industrial Group, a Saudi-listed holding company, providing financial stability and corporate governance
Named Competitors
Sanofi Middle East — Global pharma with significant MENA generic and specialty presence
Pfizer Middle East — Multinational pharmaceutical company competing in MENA generics and specialty drugs
AstraZeneca Middle East — Major global pharma with regional MENA operations
Al-Razi Pharma Industries — Saudi generic pharmaceutical manufacturer serving GCC region with SFDA cGMP certification
Zahra Pharma — Regional generic drug manufacturer providing affordable pharmaceuticals
Recent Developments
(December 2025) Partnership with Althera Laboratories for Type 2 Diabetes combination therapy distribution in MENA
(September 2025) Specialty pharmaceutical partnership with Vibativ® for pneumonia and skin infection treatment
(December 2024) Bio-Thera Solutions Inc. partnership for biosimilar commercialization
(May 2025) Awarded 'Best Contribution to the Pharmaceutical Sector – Saudi Arabia' by Global Business Outlook
Open the full interactive Tabuk Pharmaceuticals report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.